GT Biopharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
GT Biopharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • GT Biopharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $110M, a 2.92% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $110M -$3.3M -2.92% Dec 31, 2023 10-K 2024-03-26
Q4 2022 $113M -$14.9M -11.6% Dec 31, 2022 10-K 2024-03-26
Q4 2021 $128M +$25.2M +24.6% Dec 31, 2021 10-K 2023-03-30
Q4 2020 $103M +$6.05M +6.27% Dec 31, 2020 10-K 2022-03-28
Q4 2019 $96.6M +$9.35M +10.7% Dec 31, 2019 10-K 2021-04-16
Q4 2018 $87.2M +$71.3M +447% Dec 31, 2018 10-K 2020-03-27
Q4 2017 $15.9M -$5.5M -25.6% Dec 31, 2017 10-K 2019-03-29
Q4 2016 $21.4M +$5.03M +30.6% Dec 31, 2016 10-K 2018-03-01
Q4 2015 $16.4M +$1.08M +7.03% Dec 31, 2015 10-K/A 2018-02-28
Q4 2014 $15.3M +$29.8M Dec 31, 2014 10-K/A 2018-02-28
Q4 2013 -$14.4M -$396K -2.83% Dec 31, 2013 10-K 2015-03-31
Q4 2012 -$14M -$1.14M -8.83% Dec 31, 2012 10-K 2015-01-08
Q4 2011 -$12.9M Dec 31, 2011 10-K 2014-11-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.